Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: aknahow who wrote (10624)	7/6/1999 3:56:00 PM
From: Arthur Radley	Respond to of 17367

Looks like the overall market wants to roll-over at the close but XOMA is showing "some" strength. Would like to see it close on the firm side as we await the news tomorrow. Hope it will be early as I have to travel later in the morning. Always like to have a happy face on as I travel the roads of Texas.(:>)

To: aknahow who wrote (10624)	7/6/1999 4:15:00 PM
From: Edscharp	Respond to of 17367

" BIRMINGHAM, ENGLAND -- June 5, 1999 - The prospects for treating multidrug-resistant, Gram-negative bacilli don't look promising.........we must enter the new millennium with pessimism about the prospects for treatment of many of our patients who have infections with multidrug resistant Gram-negative bacilli," said Dr. David Paterson, chief of infectious diseases, Instituto Mediterraneo per i Trapianti in Palermo, Italy." George, God-forbid that this Dr. Peterson should mention Neuprex as a possible break in the clouds in the fight against gram-negative bacteria. I know its incredibly self-serving to expect a medical professional to give patients and the world a glimmer of hope on this issue. but still this guy is supposed to be Chief of Infectious Diseases at his Institute. Are Neuprex trials being kept secret from the Italian medical profession?